Teleflex Incorporated

NYSE:TFX Stock Report

Mkt Cap: US$10.9b

We’ve recently updated our valuation analysis.

Teleflex Valuation

Is TFX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TFX?

Other financial metrics that can be useful for relative valuation.

TFX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.3x
Enterprise Value/EBITDA15.8x
PEG Ratio2.5x

Price to Earnings Ratio vs Peers

How does TFX's PE Ratio compare to its peers?

The above table shows the PE ratio for TFX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average37.1x
HOLX Hologic
25.8x8.2%US$19.5b
NVST Envista Holdings
25.8x18.7%US$5.4b
MASI Masimo
70.3x27.4%US$8.3b
GMED Globus Medical
26.4x13.1%US$5.3b
TFX Teleflex
30.1x12.2%US$10.9b

Price-To-Earnings vs Peers: TFX is good value based on its Price-To-Earnings Ratio (30.1x) compared to the peer average (37.1x).

Price to Earnings Ratio vs Industry

How does TFX's PE Ratio compare vs other companies in the US Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.7%
 n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.7%
 n/an/an/a
No more companies

Price-To-Earnings vs Industry: TFX is good value based on its Price-To-Earnings Ratio (30.1x) compared to the US Medical Equipment industry average (36.3x)

Price to Earnings Ratio vs Fair Ratio

What is TFX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TFX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio30.1x
Fair PE Ratio29.2x

Price-To-Earnings vs Fair Ratio: TFX is expensive based on its Price-To-Earnings Ratio (30.1x) compared to the estimated Fair Price-To-Earnings Ratio (29.2x).

Share Price vs Fair Value

What is the Fair Price of TFX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TFX ($232.35) is trading below our estimate of fair value ($320.86)

Significantly Below Fair Value: TFX is trading below fair value by more than 20%.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TFX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$232.35
US$270.00
+16.2%
10.8%US$330.00US$211.00n/a14
May ’24US$274.11
US$266.93
-2.6%
10.8%US$330.00US$211.00n/a14
Apr ’24US$253.31
US$260.07
+2.7%
11.1%US$330.00US$211.00n/a15
Mar ’24US$233.66
US$260.07
+11.3%
11.1%US$330.00US$211.00n/a15
Feb ’24US$250.18
US$258.00
+3.1%
12.8%US$330.00US$211.00n/a15
Jan ’24US$249.63
US$254.40
+1.9%
14.0%US$330.00US$211.00n/a15
Dec ’23US$244.80
US$247.93
+1.3%
14.8%US$330.00US$211.00n/a14
Nov ’23US$219.24
US$247.93
+13.1%
14.8%US$330.00US$211.00n/a14
Oct ’23US$201.46
US$275.82
+36.9%
15.6%US$370.00US$211.00n/a11
Sep ’23US$226.65
US$280.25
+23.6%
14.5%US$370.00US$211.00n/a12
Aug ’23US$245.30
US$280.50
+14.3%
14.5%US$370.00US$211.00n/a12
Jul ’23US$255.09
US$339.91
+33.3%
16.7%US$430.00US$211.00n/a11
Jun ’23US$282.86
US$339.91
+20.2%
16.7%US$430.00US$211.00n/a11
May ’23US$285.62
US$348.70
+22.1%
16.8%US$430.00US$211.00US$274.1110
Apr ’23US$354.82
US$374.70
+5.6%
16.6%US$430.00US$211.00US$253.3110
Mar ’23US$333.24
US$373.70
+12.1%
17.3%US$430.00US$201.00US$233.6610
Feb ’23US$309.50
US$375.80
+21.4%
18.1%US$450.00US$201.00US$250.1810
Jan ’23US$328.48
US$401.80
+22.3%
18.3%US$465.00US$201.00US$249.6310
Dec ’22US$289.48
US$417.50
+44.2%
18.8%US$485.00US$193.00US$244.8010
Nov ’22US$359.24
US$417.50
+16.2%
18.8%US$485.00US$193.00US$219.2410
Oct ’22US$383.27
US$439.25
+14.6%
18.2%US$486.00US$183.00US$201.4612
Sep ’22US$397.56
US$439.18
+10.5%
19.0%US$486.00US$183.00US$226.6511
Aug ’22US$397.43
US$439.18
+10.5%
19.0%US$486.00US$183.00US$245.3011
Jul ’22US$406.84
US$446.36
+9.7%
18.8%US$486.00US$183.00US$255.0911
Jun ’22US$392.46
US$446.36
+13.7%
18.8%US$486.00US$183.00US$282.8611
May ’22US$422.48
US$446.08
+5.6%
18.1%US$486.00US$183.00US$285.6212

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies